OncoMatch/Clinical Trials/NCT06262321
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Is NCT06262321 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for stage 4 nsclc.
Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage T1-4(OR TX)N0-3M1A-C, STAGE IV, METASTATIC RECURRENCE OF PRIMARY STAGE I-III NSCLC (AJCC 8th edition)
Metastatic disease required
T1-4(or Tx)N0-3M1a-c, Stage IV disease (using the 8th edition of the AJCC staging manual) or metastatic recurrence of primary Stage I-III NSCLC that had been treated with curative intent therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: no prior thoracic radiotherapy
Prior radiation therapy to the thoracic region
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Rochester · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify